NaSSa is an acronym for "
noradrenergic and specific serotonergic antidepressants", a new type of
mood enhancing
drug that has recently been developed for sufferers of
depression.
It differs from it's predecessors SSRI's (selective serotonin re-uptake inhibitors) in that the drugs affects two neurotransmitters in the brain, serotonin and noadrenaline, selectively.
The drug is available in two forms, Remeron in the US and Zispin in Britain. The generic pharmaceutical name for the drug is mirtazapine.